Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

pancreatic cancer

This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.

Lilly partners with Merus on development of bispecific antibodies for cancer

Lilly partners with Merus on development of bispecific antibodies for cancer

In July 2020, Merus received an orphan drug designation from the US Food and Drug Administration (FDA) for its first-in-class bispecific antibody zenocutuzumab for the treatment of pancreatic cancer. ... In early clinical trials, zenocutuzumab

Latest news

  • NHS set to pilot GRAIL’s wide-ranging cancer blood test NHS set to pilot GRAIL’s wide-ranging cancer blood test

    Early detection – particularly for hard-to-treat conditions like ovarian and pancreatic cancer – has the potential to save many lives,” said Simon Stevens, chief executive of the NHS. ... This promising blood test could therefore be a game-changer

  • EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

    The approval was based on results from the phase 3 POLO trial of Lynparza (olaparib) in advanced pancreatic cancer patients whose tumours carry BRCA mutations. ... In the POLO trial, Lynparza nearly doubled median progression-free survival versus placebo

  • BMS’ Opdivo combo misses the mark in pancreatic cancer BMS’ Opdivo combo misses the mark in pancreatic cancer

    The patient population included 160 people with locally advanced or metastatic pancreatic cancer that had progressed during or after one line of chemotherapy. ... It also carries poor survival rates – less than 7% of patients are still alive five years

  • AZ revenues rise, but it says coronavirus could hit 2020 AZ revenues rise, but it says coronavirus could hit 2020

    Product sales were up 12% to $23.57bn for the full-year, driven by cancer products and turnover in emerging markets, although there was a bit of a slowdown to 8% ... Imfinzi meanwhile grew 62% to $424m, helped by increased use as maintenance therapy for

  • Eisai agrees to pull obesity drug Belviq after safety alert Eisai agrees to pull obesity drug Belviq after safety alert

    Weight-loss drug linked to increased risk of cancer. Eisai has moved swiftly to comply with an FDA request to pull its obesity drug Belviq off the market after it was ... In 2010, the FDA rejected the first marketing application for the drug, filed by

More from news
Approximately 29 fully matching, plus 119 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    the only PARP inhibitor with positive phase 3 results in four different cancer types (ovarian, breast, pancreatic and prostate). ... First we had ovarian cancer, then breast cancer, and our next steps will be for metastatic pancreatic cancer and men with

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Finding the patient voice Finding the patient voice

    Mr Whitley took part in a pancreatic cancer drug trial in 2011.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Quick links

Infographics

Multimedia